Joe Jimenez is the Co-Founder and Managing Director of Aditum Bio. See contact routes.
Joe Jimenez is the Co-Founder and Managing Director of Aditum Bio, a biotech venture fund launched in 2019 after his tenure as CEO of Novartis. His investment thesis focuses on in-licensing neglected drug candidates, forming new companies around them, and financing their progression through first-in-human trials. Aditum Bio specializes in acquiring and developing pharmaceutical assets to give patients access to medicines that may not otherwise be developed. The firm recently secured $133 million to support these startup initiatives, targeting early-stage biotechnology ventures. While specific check sizes and lead/follow behavior are not publicly detailed, the firm’s model involves creating new entities around drug candidates rather than traditional follow-on investing. Notable portfolio details are not explicitly named in available sources, though the firm’s focus remains on drug candidates with unrecognized potential left behind by larger pharma. Jimenez has publicly emphasized a focus on drug-device combinations and sees pandemic preparedness as a key area, reflecting his distinctive point of view on overlooked therapeutic opportunities.
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in San Francisco.
Investors like Joe Jimenez · Full investor directory · Investor access · Company funding database